ZYBERNO
Stock Report
Updated Sep 1, 2026

KALA BIO, Inc. (KALA)

Healthcare • NASDAQ

$0.67

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
6.0/100
POOR BUSINESS
KALA BIO, Inc. (KALA) scores 6/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-665.7%)
Debt-to-Equity (Solvency Risk):CRITICAL (3.15x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-24.5%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

KALA BIO, Inc. (KALA) stock report — Zyberno Score 6/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.67
Market Cap:$13.25M

Valuation Multiples (2)

P/B Ratio:1.47x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$68.38M
B. Profitability Assessment

Return Metrics (5)

ROA:-210.3%
Reinvestment Rate:2.0%
Fundamental Growth Rate (g):-0.5%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$2.74K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-3,203.9%
Latest Earnings Filed:2026-08-19

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-3.1%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:6.88x
Quick Ratio:6.88x
Cash Ratio:0.15x

Leverage Analysis (3)

Debt To Equity Ttm:3.15x
Debt-to-Equity Ratio:3.15x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-11.95x
Times Interest Earned:-11.95

Capital Structure (4)

Working Capital:9,044,000.00
Cash And Cash Equivalents:229,000.00
Long Term Debt:$26.95M
Net Debt:$55.13M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $0.00
Linear Growth: -3.1%
📊 Click to view full KALA Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$20.99M

Bottom Line Performance (3)

-$30.18M
Income Before Tax:$0.00
Ebitda Ttm:-20,670,000.00

Operating Expenses (5)

Operating Expenses:20,987,000.00
R And D Expense:6,613,000.00
Sga Expense:17,796,000.00
Income Tax Expense:$0.00
Interest Expense:3,276,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$10.58M
Current Assets:$10.58M
Ppe Net:869,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:1,538,000.00
Current Liabilities:1,538,000.00
Long Term Debt:$26.95M
Short Term Debt:$28.41M

Equity & Capital (3)

Equity:$9.04M
Retained Earnings:-$698.10M
Common Stock:1,500,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:1,142,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:-136,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$34.89M$0.00

Investment Activities (1)

Investing Cash Flow:-$7.00M

Financing Activities (3)

Financing Cash Flow:$4.10M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:3,394,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:317,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-24.77
-$24.77
Earnings Per Share Ttm:-$1.53

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.62

Book Value & Capital (2)

Book Value Per Share:$0.46
Cash Per Share:0.01

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:15.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:2.0%
Fundamental Growth Rate (g):-0.5%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-3.1%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-20.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:KALA
Company Name:KALA BIO, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:19.70M
Shares Outstanding Basic:74.16K
Shares Outstanding Diluted:74.16K

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 04:24:53 UTC
Data Timestamp:2026-08-20T13:22:53.997518
Scroll to Top